Novel EGFR mutation-specific antibodies for lung adenocarcinoma: Highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry

Lung Cancer

Volumn 83, Issue 3, 2014, Pages 316-323

  Seo, An Na ^a,b   Park, Tae In ^b   Jin, Yan ^a,c   Sun, Ping Li ^a,c   Kim, Hyojin ^a,c   Chang, Hyun ^a   Chung, Jin Haeng ^a,c  

^a Seoul National University Bundang Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

E746_A750 deletion; EGFR mutations; Immunohistochemistry; L858R mutation; Lung adenocarcinoma; Mutation specific antibody

Indexed keywords

E746_A750 DELETION; EGFR MUTATIONS; IMMUNOHISTOCHEMISTRY; L858R MUTATION; LUNG ADENOCARCINOMA; MUTATION-SPECIFIC ANTIBODY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; EXONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; POINT MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SEQUENCE DELETION; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84894225202     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.12.008     Document Type: Article

References (41)

1. Kitamura A., Hosoda W., Sasaki E., Mitsudomi T., Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010, 16(13):3349-3355.
2. Metro G., Finocchiaro G., Toschi L., Bartolini S., Magrini E., Cancellieri A., et al. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials 2006, 1(1):1-13.
3. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967.
4. Li A.R., Chitale D., Riely G.J., Pao W., Miller V.A., Zakowski M.F., et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008, 10(3):242-248.
5. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
6. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
7. Yu J., Kane S., Wu J., Benedettini E., Li D., Reeves C., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15(9):3023-3028.
8. Janne P.A., Engelman J.A., Johnson B.E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005, 23(14):3227-3234.
9. Xiong Y., Bai Y., Leong N., Laughlin T.S., Rothberg P.G., Xu H., et al. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol 2013, 8(1):27. 10.1186/1746-1596-8-27.
10. Brevet M., Arcila M., Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010, 12(2):169-176.
11. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21(12):2237-2246.
12. Cella D., Herbst R.S., Lynch T.J., Prager D., Belani C.P., Schiller J.H., et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005, 23(13):2946-2954.
13. Marks J.L., Broderick S., Zhou Q., Chitale D., Li A.R., Zakowski M.F., et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008, 3(2):111-116.
14. Ruschoff J., Kerr K.M., Grote H.J., Middel P., von Heydebreck A., Alves V.A., et al. Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: Round Robin Test. Arch Pathol Lab Med 2013, 137(9):1255-1261.
15. Naruse I., Ohmori T., Ao Y., Fukumoto H., Kuroki T., Mori M., et al. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 2002, 98(2):310-315.
16. Shim H.S., Chung J.H., Kim L., Chang S., Kim W.S., Lee G.K., et al. Guideline recommendations for EGFR mutation testing in lung cancer: proposal of the Korean Cardiopulmonary Pathology Study Group. Korean J Pathol 2013, 47(2):100-106.
17. Linardou H., Dahabreh I.J., Bafaloukos D., Kosmidis P., Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009, 6(6):352-366.
18. Kawahara A., Azuma K., Sumi A., Taira T., Nakashima K., Aikawa E., et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 2011, 74(1):35-40.
19. Kawahara A., Yamamoto C., Nakashima K., Azuma K., Hattori S., Kashihara M., et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010, 16(12):3163-3170.
20. Fan X., Liu B., Xu H., Yu B., Shi S., Zhang J., et al. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples. Hum Pathol 2013, 44(8):1499-1507.
21. Kim H.J., Lee K.Y., Kim Y.C., Kim K.S., Lee S.Y., Jang T.W., et al. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer 2012, 75(3):321-325.
22. Wang S., Peng L., Li J., Zeng X., Ouyang L., Tan C., et al. A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for eastern asian nonsquamous non-small-cell lung cancer. PLoS ONE 2013, 8(3):e55917.
23. Kobayashi K., Hagiwara K. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol 2013, 8(1):27-33.
24. Sun P.L., Jin Y., Kim H., Lee C.T., Jheon S., Chung J.H. High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas. Cancer Cytopathol 2013, 121(6):311-319.
25. Moskalev E.A., Stohr R., Rieker R., Hebele S., Fuchs F., Sirbu H., et al. Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing. Virchows Arch 2013, 462(4):409-419.
26. Da Cunha Santos G., Saieg M.A., Geddie W., Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011, 119(2):80-91.
27. Simonetti S., Molina M.A., Queralt C., de Aguirre I., Mayo C., Bertran-Alamillo J., et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 2010, 18(8):135. 10.1186/1479-5876-8-135.
28. Kato Y., Peled N., Wynes M.W., Yoshida K., Pardo M., Mascaux C., et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010, 5(10):1551-1558.
29. Wu S.G., Chang Y.L., Lin J.W., Wu C.T., Chen H.Y., Tsai M.F., et al. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS ONE 2011, 6(8):e23303.
30. Yoo S.B., Lee H.J., Park J.O., Choe G., Chung D.H., Seo J.W., et al. Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: a comparison with fluorescence in situ hybridization study. Lung Cancer 2010, 67(3):301-305.
31. Paik J.H., Choe G., Kim H., Choe J.Y., Lee H.J., Lee C.T., et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011, 6(3):466-472.
32. Ruschoff J., Dietel M., Baretton G., Arbogast S., Walch A., Monges G., et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010, 457(3):299-307.
33. Yoo S.B., Chung J.H., Lee H.J., Lee C.T., Jheon S., Sung S.W. Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung. J Thorac Oncol 2010, 5(7):964-969.
34. Lee H.J., Xu X., Kim H., Jin Y., Sun P., Kim J.E., et al. Comparison of direct sequencing, PNA clamping-real time polymerase chain reaction, and pyrosequencing methods for the detection of EGFR mutations in non-small cell lung carcinoma and the correlation with clinical responses to EGFR tyrosine kinase inhibitor treatment. Korean J Pathol 2013, 47(1):52-60.
35. Duffaud F., Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 2000, 87(12):881-886.
36. Paik J.H., Choi C.M., Kim H., Jang S.J., Choe G., Kim D.K., et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012, 76(3):403-409.
37. Kozu Y., Tsuta K., Kohno T., Sekine I., Yoshida A., Watanabe S., et al. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 2011, 73(1):45-50.
38. Hofman P., Ilie M., Hofman V., Roux S., Valent A., Bernheim A., et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 2012, 23(7):1738-1743.
39. Hasanovic A., Ang D., Moreira A.L., Zakowski M.F. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer 2012, 77(2):299-305.
40. Jiang G., Fan C., Zhang X., Dong Q., Wang L., Liu Y., et al. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer. PLoS ONE 2013, 8(3):e59183.
41. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., Giaccone G., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013, 8(7):823-859.